In support of this finding, a Korean cohort study revealed that SGLT2 inhibitors reduce dementia and PD risk in type 2 diabetes patients, underscoring the neuroprotective potential of improving insulin resistance (Kim et al., 2024). Here, SLC5A2 is linked to type 2 diabetes mellitus.